130 related articles for article (PubMed ID: 1715415)
1. [Combination chemotherapy with methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin (MVP-CAB) for metastatic urothelial cancer].
Fujii A; Oka N; Miyasaki S; Higuchi A; Itoh N; Okamoto Y; Tanaka H; Hiro-oka K; Shimatani N; Inoue T
Nihon Hinyokika Gakkai Zasshi; 1991 Jun; 82(6):932-9. PubMed ID: 1715415
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract].
Fujii A; Oka N; Murata Y; Higuchi A; Itoh N; Ishikawa J; Tanaka H
Nihon Hinyokika Gakkai Zasshi; 1992 Oct; 83(10):1609-14. PubMed ID: 1279258
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].
Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Itoh N; Nakagawa Y; Miyazaki S
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):55-62. PubMed ID: 1691254
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy (MVP-CAB; methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin) for bladder cancer].
Fujii A; Oka N; Murata Y; Higuchi A; Itoh N; Nakagawa J; Tanaka H; Izumi T; Yamada Y
Nihon Hinyokika Gakkai Zasshi; 1992 May; 83(5):619-26. PubMed ID: 1379656
[TBL] [Abstract][Full Text] [Related]
6. [A study of the use of methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, bleomycin (MVP-CAB) in metastatic transitional cell carcinoma].
Fujii A; Den S; Nakamura I; Ohshima H; Nagata H; Izumi T; Takechi Y; Kawaida T; Kamidono S; Yasuno H
Hinyokika Kiyo; 1987 May; 33(5):697-703. PubMed ID: 2444083
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up results of a Pilot Phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer.
Gohji K; Ono Y; Takenaka A; Nomi M; Okamoto M; Yuen K; Fujii A
Jpn J Clin Oncol; 1999 Apr; 29(4):204-8. PubMed ID: 10340044
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Izumi T; Miyasaki Z; Ito N
Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):985-93. PubMed ID: 2460657
[No Abstract] [Full Text] [Related]
9. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
[TBL] [Abstract][Full Text] [Related]
10. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
Yamauchi T; Hida S; Ooishi K; Okada K; Yoshida O
Hinyokika Kiyo; 1985 Jul; 31(7):1093-104. PubMed ID: 2414981
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate.
Kubota Y; Shuin T; Miura T; Moriyama M; Fukushima S; Shiozaki H; Ooshima H
Cancer Treat Rep; 1984 Sep; 68(9):1167-8. PubMed ID: 6206946
[TBL] [Abstract][Full Text] [Related]
12. Intensive sequential chemotherapy with bleomycin, Oncovin, mitomycin C, and methotrexate followed by adriamycin, cisplatin, and cyclosphosphamide in squamous cell cancer of the head and neck.
Wheeler RH; Baker SR; Liepman MK; Ensminger WD
Med Pediatr Oncol; 1983; 11(1):12-9. PubMed ID: 6188032
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer.
Pectasides D; Mylonakis A; Antoniou F; Kostopoulou M; Triantaphyllis D; Papadopoulou M; Varthalitis J; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(2):139-44. PubMed ID: 9499188
[TBL] [Abstract][Full Text] [Related]
14. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II) and adriamycin in urothelial cancer].
Konami T; Wakabayashi Y; Kim T; Ishida A; Arai Y; Konishi T; Pak K; Takeuchi H; Tomoyoshi T; Watanabe J
Hinyokika Kiyo; 1989 Feb; 35(2):231-7. PubMed ID: 2472048
[TBL] [Abstract][Full Text] [Related]
15. [Intraarterial COMPA (cis-diammine-dichloroplatinum (II), vincristine, methotrexate, peplomycin, adriamycin) chemotherapy for bladder cancer].
Tsujino S; Ito T; Aizawa T; Namiki K; Ohno Y; Yamamoto S; Ishibashi K; Miki M; Yamauchi T; Kawai T
Hinyokika Kiyo; 1992 Oct; 38(10):1101-7. PubMed ID: 1282770
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
[TBL] [Abstract][Full Text] [Related]
20. Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
Ohshima S; Ono Y; Fujita T; Aso Y
Cancer Chemother Pharmacol; 1987; 20 Suppl():S20-3. PubMed ID: 2444354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
